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The terms methylation quantiﬁcation and qualiﬁcation seem self-explanatory however, the
results of experiments aiming to quantify or qualify locus speciﬁc methylation in clini-
cal material are often difﬁcult to interpret. There are three main reasons for difﬁculties in
understanding methylation status measurement. First, the complexity of locus speciﬁc
methylation patterns, which oscillate between unmethylated, fully methylated, and het-
erogeneously methylated. Second the interpretation of methylation-screening results can
frequently be problematic due to limitations of the methods used. And ﬁnally the speciﬁca-
tions of the clinical samples used in laboratory practice frequently hamper the methylation
measurement. Thus, the process of quantiﬁcation and qualiﬁcation of methylation has to
be discussed with consideration of the speciﬁc locus analyzed, the methodology used, and
the clinical material source used in each speciﬁc experiment. The question of the clinical
signiﬁcance of determination of different methylation levels is even more complicated, with
substantial evidence for correlation between qualitative methylation changes and clinical
features of the disease and at the same time no data showing that different relative levels
of methylation alter the disease outcome.The limitations of methylation quantiﬁcation and
qualiﬁcation are discussed in this mini-review.
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METHYLATION
DNAmethylation in humans generally describes a process of addi-
tion of a methyl group to carbon 5 of cytosine (5-mC) within a
5′-CpG-3′ dinucleotide. In normal cell physiology DNA methy-
lation modulates gene expression. Deregulation of the normal
pattern of methylation leads to aberrant expression of the genes,
which in turn can initiate the disease or contribute to the disease
phenotype (Esteller, 2008). Hence, measurements of the methyla-
tion status of the CpG dinucleotides become very important from
both a biological and a medical/clinical point of view.
COMPLEXITY OF PCR BASED MEASUREMENT OF
METHYLATION
USE OF PCR IN METHYLATION STUDIES
The vast majority of techniques currently used for measurement
of methylation are based on PCR ampliﬁcation. However, the use
of PCR ampliﬁcation in methylation studies is not straightfor-
ward. In the cell, methylation marks are added to the replicated
DNA strand in a semi conservative fashion by DNMTs (DNA
methyltransferase). No DNMTs are present in standard PCR and
information on methylation status of CpG sites is lost in the
ﬁrst round of PCR. Therefore, in methylation studies prior to the
use of PCR, the methylation marks have to be preserved on the
template DNA. Modiﬁcation of the template DNA with sodium
bisulﬁte is most commonly used to preserve methylation marks
before PCR ampliﬁcation. Sodium bisulﬁte implements methy-
lation dependent base changes in the DNA strand by converting
cytosines into uracil and leaving 5-mC intact. The ampliﬁcation
of bisulﬁte-modiﬁed template results in different nucleotide com-
position of the ampliﬁcation product depending on whether it
originates from a methylated, unmethylated, or heterogeneously
methylated template (Figure 1).
DESIGN OF PCR FOR AMPLIFICATION OF BISULFITE-MODIFIED
TEMPLATE
When analyzing methylation of a number of CpG sites in a DNA
strand of certain length, three scenarios are possible: all CpG sites
within the sequence of interest can be devoid of methylation, or
can be methylated and the third scenario is referred to as a hetero-
geneous methylation status where a different number of CpG sites
can be methylated at different alleles (Figure 2). The PCR ampli-
ﬁcation in methylation studies can speciﬁcally target fully methy-
lated or unmethylated variant of the locus [methylation-speciﬁc
PCR (MSP) based ampliﬁcation, see below] or can amplify the
locus of interest regardless of the methylation status for post-PCR
methylation analyses [methylation independent primers (MIP)
based ampliﬁcation].
MSP BASED APPROACH
When using the MSP based approach the primers are in principle
designed to amplify only fully methylated template (another set
can potentially be designed to target unmethylated template; Her-
man et al., 1996). In order to achievemethylation-speciﬁc ampliﬁ-
cation, the primer set has to, in general, contain as many CpG sites
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as possible. This will ensure speciﬁc binding only to the template
where all the CpG sites aremethylated and therefore not converted
by sodiumbisulﬁte. For this technologyno ampliﬁcation is allowed
from partly methylated (heterogeneously methylated) templates
and the stringency of PCR conditions have to be optimized
to ensure speciﬁc ampliﬁcation. If any ampliﬁcation from mis-
matched primers (partly methylated templates) takes place, the
assay cannot be considered reliable due to the possibility of gen-
erating false positive ampliﬁcations (Aggerholm and Hokland,
2000). To obtain quantitative measurement of fully methylated
template in the sample, a ﬂuorescent probe can be ﬂanked byMSP
primers or DNA intercalating dye can be added to PCR [methods
called Q (quantitative)-MSP or MethyLight] to enable real-time
monitoring of the ampliﬁcation (Trinh et al., 2001).
MIP BASED APPROACH
Methylation independent primers based technologies utilize
primers that aim to amplify the locus of interest regardless
of its methylation status in the same PCR (Clark et al., 1994;
Wojdacz et al., 2008c). The PCR product ampliﬁed with MIP
primers will differ in base content depending whether it origi-
nates from methylated, unmethylated, or heterogeneously methy-
lated templates. In this approach a post-PCR technology, e.g.,
melting or sequencing is required to investigate the methyla-
tion status of the sample (Wojdacz and Hansen, 2006). It is
important to keep in mind that when using the MIP approach
FIGURE 1 | Principles of bisulfite modification where methylated CpG
sites remain unchanged while cytosines are converted to uracil.
the post-PCR methylation “read out” reﬂects the average state
of methylation of single CpG site for all the PCR products
present in the sample. Unless technologies like cloning of PCR
products followed by sequencing (pyrosequencing or Sanger
sequencing) or second-generation sequencing are used in com-
bination with MIP based ampliﬁcations no information on the
methylation status of single alleles (PCR products) in the sam-
ple can be obtained (Clark et al., 1994; Fazzari and Greally,
2010).
PCR BIAS IN MIP BASED AMPLIFICATIONS
Proportional ampliﬁcation of methylated and unmethylated tem-
plates with one primer set in a single PCR is in most cases com-
promised by the PCR bias phenomenon (Wojdacz et al., 2009).
PCR bias in methylation studies is described as preferential ampli-
ﬁcation of the unmethylated template (Warnecke et al., 1997).
Modiﬁcation of the PCR chemistry has been shown not to elimi-
nate the PCR bias fromMIP based ampliﬁcations (Warnecke et al.,
1997).However, speciﬁcprimerdesign and empirical optimization
of the PCR conditions have been shown to resolve the PCR bias
problem and reassure proportional ampliﬁcation of methylated
and unmethylated templates (details of the design can be found in
Wojdacz et al., 2008c).
INTERPRETATION OF PCR BASED
METHYLATION-SCREENING RESULTS
QUALITATIVE METHYLATION MEASUREMENT
To assess methylation in a qualitative manner means to show that
the methylated (or unmethylated) sequence of interest is present
in the screened sample at detection level that is characteristic for a
givenmethylation detection technology. BothMSP andMIP based
methods can be used to qualify methylation. The qualitative result
cannot be discussed in the context of methylation levels but only
indicate presence or absence of methylation. The only instance
when qualitative results are referred to as “methylation levels” in
the literature is when reporting a number of methylation posi-
tive samples in a total number of screened samples. However, the
term “the methylation frequency” is more accurate in this case.
Over the years MSP was the gold standard method for qualiﬁca-
tion of methylation. This method however, only conﬁrms the fully
methylated status of the CpG sites within primer binding sites.
WhenMIP ampliﬁcation is used, not only overall methylation sta-
tus of the amplicon can be qualiﬁed by post-PCR technologies
like high resolution melting (HRM), but also the methylation pat-
tern within the amplicon can be investigated if MIP ampliﬁcation
is combined with sequencing based technologies (Wojdacz et al.,
2010; Candiloro et al., 2011).
FIGURE 2 |Three stages of methylation of the locus: fully methylated, fully unmethylated, and heterogeneously methylated.
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QUANTITATIVE METHYLATION MEASUREMENT
To quantify methylation means to “count” all the differently
methylated molecules in the sample. Quantiﬁcation of fully
methylated (or fully unmethylated)molecules is relatively easy and
can be described as percentage of methylated (or unmethylated)
molecules of the overall number ofmolecules in the sample.Quan-
tiﬁcation of heterogeneous methylation is challenging. It requires
sequencing of every single heterogeneouslymethylated allele in the
screened sample, which currently only can be accomplished using
next generation sequencing technologies (see below for detailed
description).
The MSP approach can be utilized to investigate the number
of fully methylated molecules in the sample. However the MSP
primers have to be combined with a ﬂuorescent probe or an
intercalating dye to enable real-time monitoring of the increas-
ing amount of the PCR product (Eads et al., 2000; Harden et al.,
2003).
TheMIP approach can also be used to quantifymethylation lev-
els, however thismeasurement is based ondifferent principles than
MSP basedmethylation level assessment. TheMIP basedmethyla-
tion levelmeasurement relies on the assumption that the post-PCR
proportion of the PCR product originating from the methylated
and unmethylated templates, reﬂects the pre-PCR proportion of
methylated to unmethylated templates (assuming that PCR bias
during ampliﬁcation is controlled; Wojdacz and Dobrovic, 2007;
Wojdacz et al., 2008b, 2009; Balic et al., 2009; Stanzer et al., 2010).
Different methods can be used to measure the post-PCR pro-
portion of “methylated” to “unmethylated” PCR products. Direct
sequencing (or pyrosequencing) of MIP ampliﬁcation products
enables estimation of the average methylation levels at each CpG
site (heights of the sequencing peaks at CpG sites). However due
to limitations of the sequencing technologies (e.g., relatively low
sensitivity) interpretation of the results can often be challenging
(Wojdacz et al., 2010). Cloning and sequencing are signiﬁcantly
more precise but cost and labor consuming (Clark et al., 1994).
At the same time, the result of single cloning and sequencing
experiment is qualitative and reveals the methylation pattern of
single allele. However, if the results of sequencing results for given
locus from more than one clone are reported, the methylation
frequency at each CpG site can be averaged over the number of
clones and reported as methylation level. This is a very power-
ful technology allowing investigation of the methylation pattern
of single alleles, but at the same time its precision with regard to
methylation levels assessment depends on the number of clones
sequenced.
Apart from sequencing technologies two other techniques
methylation sensitive high resolutionmelting (MS-HRM) or com-
bined bisulﬁte restriction analysis (COBRA) are currently most
frequently utilized to measure the proportion of methylated to
unmethylated PCR product after MIP ampliﬁcation (Xiong and
Laird, 1997; Wojdacz and Dobrovic, 2007). In MS-HRM methy-
lation levels in screened samples can be calculated by means of
comparison of the HRM proﬁle of PCR product characteristic for
the screened samples to the HRM proﬁles of the PCR products
obtained by ampliﬁcation of the mixes of artiﬁcially methylated
and unmethylated standards with know proportion of methylated
to unmethylated template (Wojdacz et al., 2008b). When using
COBRA approach, quantiﬁcation of enzymatic digestion products
and comparison to the amount of the digest from control samples
are used as surrogate measurement of methylation levels (Xiong
and Laird, 1997).
MEASUREMENT OF HETEROGENEOUS METHYLATION
Only MIP based primers can be used to amplify heterogeneously
methylated loci. The PCR product obtained after ampliﬁcation
of heterogeneously methylated loci derives from a vast num-
ber of alleles with different methylation pattern (Wojdacz et al.,
2010; Candiloro et al., 2011). Currently, only second-generation
sequencing technologies have the capacity to visualize the allelic
variations in heterogeneouslymethylated samples. In the instances
where approximate data on methylation status of single CpG sites
within each allele in heterogeneouslymethylated sample is needed,
approaches based on cloning and sequencing (as described above)
can be applied. Identiﬁcation of heterogeneous methylation in
the sample can be performed by MS-HRM which currently is the
only PCR based technique that can robustly identify PCR products
derived from heterogeneously methylated samples as they display
characteristic HRM proﬁle (Wojdacz et al., 2010). However, MS-
HRM results are not quantitative with regards to heterogeneous
methylation and do not indicate methylation status of particular
CpG sites within the sequence of interest.
In principle heterogeneous methylation can only be described
as a qualitative pattern of the methylated CpG sites within the
screened amplicon at each allele present is the sample. Con-
sequently heterogeneous methylation should be reported, as a
graphical illustration of different patterns of methylation for each
speciﬁc screened allele. It is relatively easy to do, for the exper-
iments employing cloning and sequencing of bisulﬁte-modiﬁed
templates as those experiments normally involve a limited num-
ber of alleles in the samples. However it may be challenging for
second-generation sequencing. Reporting heterogeneous methy-
lation as average levels of methylation for each CpG site within
the sequenced template can be very confusing. That is due to
the fact that the raw result of Sanger/pyrosequencing of het-
erogeneously methylated templates is very similar to the results
of sequencing of the sample containing a mix of fully methy-
lated and unmethylated template (Wojdacz et al., 2010). There is
however one instance where the averaged percentage of methy-
lation for a number of clones sequenced from heterogeneously
methylated sample can be used. It is known that within some
loci single CpG sites undergo methylation independently and
methylation is “seeded” at particular CpG sites over time, until
all CpG sites within a sequence become methylated, e.g., dur-
ing cancer progression from benign to malignant tumor or aging
(Mikeska et al., 2010; Oster et al., 2011). The intermediate stage
between fully methylated and unmethylated is in principle a
heterogeneously methylated stage of the alleles. Therefore, to
illustrate this gradual process of locus methylation, reporting
an averaged number of methylated CpG sites over time, can be
useful.
CLINICAL MATERIAL AS A LIMITING FACTOR FOR
QUANTIFICATION AND QUALIFICATION OF METHYLATION
In every day laboratory practice almost all clinical samples
screened for methylation contain, apart form the tissue tar-
geted by a given experiment, a fraction of different tissues. The
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“contaminating” fraction of tissues/cells is a consequence of the
sample collection procedure, and may frequently constitute a
considerable part of clinical specimen. It is relatively easy to qual-
ify the methylation in such a sample, as the contamination does
not interfere with technologies that can identify even a single
molecule that undergoing hyper- or hypomethylation as long as
the detection limit of the method is sufﬁciently high. However,
when quantifying locus speciﬁc methylation in clinical samples
the ratio between the abnormal (target) tissue/cells in the sample
and the normal tissue/cells (e.g., tissue from which the abnormal
tissue was dissected) will signiﬁcantly inﬂuence quantiﬁcation of
methylation. The measurement of methylation levels in a sample
with unknown fraction of contaminating tissues reﬂects only the
methylation level in the given sample, and cannot be directly com-
pared with the measurement of methylation in another sample
where the fraction of contaminating tissues was not evaluated. In
some cases the fractionof abnormal tissue in the clinical specimens
can be evaluated prior to methylation analyses (e.g., microdis-
section or evaluation by pathologist) but normalization for the
fraction of “contaminating tissue” in the sample is very difﬁcult to
implement in laboratory practice.
The second limitation of methylation quantiﬁcation in labora-
tory practice is the heterogeneity of methylation within abnormal
tissue, which is a product of different methylation pattern of
alleles in abnormal tissue. The above phenomenon is seen in
almost all cancer tumors, which develop, by accumulation of
genetic/epigenetic abnormalities and clonal expansion. There is
no robust method to evaluate tumor heterogeneity and therefore
it is virtually impossible to normalize for tumor heterogeneity
when investigating methylation levels. Moreover, DNA degrada-
tion can occur during sample collection and sample processing
procedure involving ﬁxation. And this can signiﬁcantly inﬂuence
the results.
QUALIFICATION AND QUANTIFICATION OF METHYLATION
FOR CLINICAL APPLICATIONS
Potentially any methylation level detected in abnormal tissue can
be clinically relevant especially in cancer researchwhen a small part
of tumor cells harboring methylated alleles can represent a part of
the tumor, resistant to treatment. There is a lot of evidence that
qualitativemethylation assessment in the clinical sample correlates
with clinical outcome. At the same time there is lack of evidence
in the literature that two samples of the same malignant tissue
(e.g., two breast cancer tumors) with relatively different methyla-
tion level at given loci, e.g., 50 and 70% correlate differently with
the disease outcomes. Such a correlation has only been shown
for imprinted loci where 50% methylation reﬂects methylation
of one allele, 100% methylation of both alleles and 0% loss of
methylation (Wojdacz et al., 2008a). However, this does not mean
that only qualiﬁcation of locus speciﬁc methylation and qualita-
tive methods are sufﬁcient for diagnostic applications. Recently
a lot of attention is paid to the so-called low-levels of methy-
lation that can be found in normal tissues and which do not
appear to have pathological consequences (Wallace et al., 2010;
Wojdacz et al., 2011a,b). Potential signiﬁcance of this phenom-
enon in disease development is largely unknown. However, the
fact that for some loci low-level methylation in healthy tissue
turns into high levels methylation in abnormal tissue as a conse-
quence of pathological processes, suggests a potential signiﬁcance
of low-level methylation for disease development. The increase
of methylation levels in transformed tissue at affected loci can
be explained by a stepwise theory of malignant transformation.
Where the cell(s) with the acquired aberrant methylation (low-
level methylation in normal tissue) only develops into malignant
tissue when other initiating events occur and render affected cell
capable of clonal proliferation. The clonal proliferation of cells
harboring abnormallymethylated loci results high levels of methy-
lation of those loci seen in neoplastic tissue. When a qualitative
method is used for methylation measurement, non-pathological
(low-level)methylation can bemistaken for the pathologically sig-
niﬁcant methylation level. Therefore, despite the fact that at the
current stage of knowledge only qualitative assessment of methyla-
tion was shown to have clinical applications the methods used for
diagnostic methylation assessment have to be quantitative. Only
quantitativemethods allow (if needed) a cut-off point for the clin-
ically signiﬁcant methylation level to be established (Reinert et al.,
2011).
CONCLUDING REMARKS
The primary issue in evaluation of clinical applicability of disease
dependentmethylation change at speciﬁc loci is correct interpreta-
tion of the results and awareness of the limitations of experimental
protocols. The vast number of studies in the ﬁeld has been shown
to report discrepant results. One of the most vivid examples of the
methodological shortcoming in the ﬁled is a multicenter study by
Hegi et al. (2005) which concluded: “The success rate of MSP
on parafﬁn-embedded tumor samples was highly variable and
center-dependent” or study by Aggerholm and Hokland (2000).
The above may indicate the fact that not all limitations of the
experiments are taken in to account when conclusions are drawn.
Thus described here basic issues with the results interpretation in
methylation studies should be considered in each study aiming to
evaluate the clinical applicability of the disease dependent, locus
speciﬁc methylation changes.
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